Brief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer
28/05/2026 13:48
BRIEF-RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer May 28 (Reuters) - RenovoRx Inc RNXT.O:
ANNOUNCES FDA ORPHAN DRUG DESIGNATION GRANTED: OXALIPLATIN FOR THE TREATMENT OF PANCREATIC CANCER
ODD PROVIDES SEVEN YEARS OF MARKET EXCLUSIVITY UPON FDA APPROVAL
TIGER-PAC TRIAL ENROLLMENT TO CLOSE JUNE 2026, FINAL DATA READOUT MID TO LATE 2027
Source text: ID:nGNXs853c
Further company coverage: RNXT.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: Renovorx Advances Tamp Into Borderline Resectable Pancreatic Cancer With First Patient Enrolled In Investigator-Initiated Prism-Tamp Trial
RenovoRx Inc reports results for the quarter ended June 30 - Earnings Summary
Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
Brief: RenovoRx Q2 Net Income USD -2.911 Million
Brief: Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer